- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Empowering Patients: Effective Dermatologic Treatment Selection for Hand and Feet AD
Dr Golant continues with the case of the 38-year old patient with atopic dermatitis and explore effective strategies for navigating treatment selection and planning in this condition, focusing on discussing options with patients and instilling confidence in the chosen approach.
EP: 1.Prevalence and QoL of Hand and Foot AD
EP: 2.Barrier Function and Atopic Dermatitis
EP: 3.Disease Severity's Influence on Atopic Dermatitis Therapeutic Selection
EP: 4.The AD Journey of a Construction Worker: Insights from a 38-Year-Old Caucasian Male
EP: 5.Empowering Patients: Effective Dermatologic Treatment Selection for Hand and Feet AD
EP: 6.Understanding Drug Interactions in Systemic Treatment: Impact on Atopic Dermatitis Symptoms
EP: 7.Practice Pearls for Optimizing the Management of Hand and Foot Atopic Dermatitis
This is a video synopsis of a discussion involving Alexandra Golant, MD, Assistant Professor at the Icahn School of Medicine at Mount Sinai, focusing on treatment options for patients with atopic dermatitis (AD), particularly those with hand and foot involvement.
Dr. Golant advocates for providing patients with a comprehensive overview of treatment options and discourages reliance solely on topical therapies without considering alternative approaches. She emphasizes early discussions about transitioning to systemic treatments if topical therapies fail to provide adequate control, offering patients a backup plan and instilling hope for improved outcomes.
In assessing patients for systemic therapy, Dr. Golant considers factors such as disease control, treatment burden, and quality of life. She discusses various systemic options, including biologics like dupilumab and tralokinumab, as well as oral Janus kinase (JAK) inhibitors. Each option is tailored based on patient preferences, comorbidities, and safety considerations.
Dupilumab, in particular, has shown consistent efficacy in hand and foot AD, with recent studies supporting its use in these areas. Dr. Golant recommends regular follow-up visits to monitor treatment response and adjust therapy as needed, with closer monitoring for patients on oral JAK inhibitors due to safety concerns.
Overall, Dr. Golant highlights the array of effective treatment options available for AD in 2024, emphasizing the importance of individualized care and shared decision-making to optimize outcomes for patients with this chronic condition.
Video synopsis is AI-generated and reviewed by Dermatology Times® editorial staff.
